HAL Allergy
ent_e0645214c12d1666b48893f3
Disclosures
2
Leak Site · 1 jurisdiction
Incidents
—
no linked incident in sample
Max affected reported
—
no filed count in sample
Leak-site claims
2
unverified actor claims
Identity resolution
- Canonical name
- HAL Allergy
- Normalized
- hal allergy— dedupe via name-norm; Microsoft / MSFT collapse to one row
- GLEIF LEI
- No match
- SEC EDGAR CIK
- None — not an SEC registrant
- Domain
- hal-allergy.com
Unverified threat-actor claim — not a regulatory filing
Attribution, victim identity, and counts shown here derive from a threat actor's public extortion-blog claims, aggregated by ransomware.live. They have not been validated by the victim or any regulator. Treat them as the threat actor's assertion until a regulatory filing or victim disclosure corroborates them.
Disclosure history (2)newest first
- GLOBALLeak Siteas victim2024-02-18
HAL Allergy is one of the European top players in the development, production and distribution of allergen immunotherapies for the treatment and prevention of allergic diseases. With a highly competitive product portfolio, including subcutaneous and sublingual products, and a future-oriented pipeline portfolio, HAL Allergy strives to provide the best possible medical products and scientific output. HAL Allergy is located in the Bio Science Park in Leiden, The Netherlands.
- GLOBALLeak Siteas victim2023-11-02
HAL Allergy is one of the leading companies in the field of allergen diagnostic and immunotherapies in Europe. The allergy therapies are used against common allergies such as hay fever, house dust mites allergy and allergic reactions towards wasp or bee stings. The company works intensively in collaboration with its sales organizations, distributors and internationally acclaimed research institutes to bring out the best possible combination of knowledge and experience. The company focuses on the core group of allergy experts from the specialties of ENT, Dermatology and Pulmonology. HAL Allergy has the most modern and state-of-the-art production facility at its main site in the Bio Science Park at Leiden in the Netherlands. Currently their products are marketed in 16 countries. Moreover this leading manufacturer of therapeutic and diagnostic agents for allergies has sales organizations in all the major European markets including Germany, Poland, Austria, Italy and Spain.